{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:19:18Z","timestamp":1783347558791,"version":"3.54.6"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Annual immunisation against COVID-19 and seasonal influenza before the winter waves is increasingly recommended in routine practice. These vaccines may be administered on the same day or sequentially, yet data on the immunogenicity of consecutive vaccinations in patients on dialysis remain limited. In this real-world observational study, we assessed SARS-CoV-2-specific immune responses in dialysis patients receiving the monovalent XBB.1.5-vaccine followed by a quadrivalent influenza vaccine 14 days later, or either vaccine alone. Antigen-specific antibodies and T cells were quantified using enzyme-linked immunosorbent assays and flow cytometry. Baseline analyses showed that most patients had detectable SARS-CoV-2- and influenza-specific immunity prior to the vaccination season. Both vaccines substantially boosted pre-existing humoral and cellular responses. Among XBB.1.5-vaccinated patients, subsequent influenza vaccination did not alter the magnitude of spike-specific antibody or T-cell responses. Likewise, influenza vaccination had no non-specific effect on SARS-CoV-2-specific immunity. Spike-specific responses remained stable for six months and persisted at levels exceeding those of unvaccinated patients assessed during the same period. Sequential administration of COVID-19 and influenza vaccines in patients on dialysis is feasible and was not associated with compromised immunogenicity of either vaccine. These findings support the use of booster vaccination in these patients and inform future deployment of additional mRNA-based vaccines.<\/jats:p>","DOI":"10.1038\/s41598-026-60726-0","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:26:27Z","timestamp":1783337187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2-specific immunity after XBB.1.5 vaccination is not significantly altered by subsequent influenza vaccination in dialysis patients"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-1268","authenticated-orcid":false,"given":"Saskia","family":"Bronder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2677-5118","authenticated-orcid":false,"given":"Rebecca","family":"Urschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0357-6828","authenticated-orcid":false,"given":"Janine","family":"Mihm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lora","family":"Schlienger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-5283","authenticated-orcid":false,"given":"Tina","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-5595","authenticated-orcid":false,"given":"Urban","family":"Sester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-0002","authenticated-orcid":false,"given":"Martina","family":"Sester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"60726_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejim.2004.01.006","volume":"15","author":"D Wat","year":"2004","unstructured":"Wat, D. The common cold: a review of the literature. Eur. J. Intern. Med. 15, 79\u201388 (2004).","journal-title":"Eur. J. Intern. Med."},{"key":"60726_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1473-3099(05)70270-X","volume":"5","author":"R Eccles","year":"2005","unstructured":"Eccles, R. Understanding the symptoms of the common cold and influenza. Lancet Infect. Dis. 5, 718\u2013725 (2005).","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl 4","key":"60726_CR3","doi-asserted-by":"publisher","first-page":"S284","DOI":"10.1093\/cid\/cir043","volume":"52","author":"AT Pavia","year":"2011","unstructured":"Pavia, A. T. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin. Infect. Dis. 52 (Suppl 4), S284\u2013289 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"60726_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1093\/ndt\/14.12.2807","volume":"14","author":"M Girndt","year":"1999","unstructured":"Girndt, M., Sester, U., Sester, M., Kaul, H. & K\u00f6hler, H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol. Dial Transpl. 14, 2807\u20132810 (1999).","journal-title":"Nephrol. Dial Transpl."},{"key":"60726_CR5","doi-asserted-by":"publisher","first-page":"105335","DOI":"10.1016\/j.ebiom.2024.105335","volume":"108","author":"F Hielscher","year":"2024","unstructured":"Hielscher, F. et al. The inactivated herpes zoster vaccine HZ\/su induces a varicella zoster virus specific cellular and humoral immune response in patients on dialysis. EBioMedicine 108, 105335 (2024).","journal-title":"EBioMedicine"},{"key":"60726_CR6","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1016\/j.vaccine.2013.06.076","volume":"31","author":"U Sester","year":"2013","unstructured":"Sester, U. et al. Serial influenza-vaccination reveals impaired maintenance of specific T-cell memory in patients with end-stage renal failure. Vaccine 31, 4111\u20134120 (2013).","journal-title":"Vaccine"},{"key":"60726_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-024-00816-0","volume":"9","author":"S Bronder","year":"2024","unstructured":"Bronder, S. et al. Potent induction of humoral and cellular immunity after bivalent BA.4\/5 mRNA vaccination in dialysis patients. NPJ Vaccines. 9, 25 (2024).","journal-title":"NPJ Vaccines"},{"key":"60726_CR8","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S1473-3099(23)00783-1","volume":"24","author":"A Cossmann","year":"2024","unstructured":"Cossmann, A. et al. Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany. Lancet Infect. Dis. 24, e145\u2013e146 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"60726_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMc2214293","volume":"388","author":"ME Davis-Gardner","year":"2023","unstructured":"Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl. J. Med. 388, 183\u2013185 (2023).","journal-title":"N Engl. J. Med."},{"key":"60726_CR10","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1093\/ckj\/sfad230","volume":"16","author":"P Affeldt","year":"2023","unstructured":"Affeldt, P. et al. Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients. Clin. Kidney J. 16, 2757\u20132759 (2023).","journal-title":"Clin. Kidney J."},{"key":"60726_CR11","first-page":"7","volume":"21","author":"J Koch","year":"2023","unstructured":"Koch, J. et al. Empfehlung der STIKO zur Implementierung der COVID-19-Impfung in die Empfehlungen der STIKO 2023 und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. Epid Bull. 21, 7\u201348 (2023).","journal-title":"Epid Bull."},{"key":"60726_CR12","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.lanepe.2023.100628","volume":"29","author":"EA Dulfer","year":"2023","unstructured":"Dulfer, E. A. et al. Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. Lancet Reg. Health Eur. 29, 100628 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"60726_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmi.2022.12.008","volume":"29","author":"H Radner","year":"2023","unstructured":"Radner, H. et al. Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers. Clin. Microbiol. Infect. 29, 635\u2013641 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"60726_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","volume":"398","author":"R Lazarus","year":"2021","unstructured":"Lazarus, R. et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet 398, 2277\u20132287 (2021).","journal-title":"Lancet"},{"key":"60726_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","volume":"10","author":"R Izikson","year":"2022","unstructured":"Izikson, R. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged\u2009\u2265\u200965 years: a phase 2, randomised, open-label study. Lancet Respir Med. 10, 392\u2013402 (2022).","journal-title":"Lancet Respir Med."},{"key":"60726_CR16","unstructured":"Kommission f\u00fcr Hygiene und Infektionspr\u00e4vention der DGfN. Empfehlung zu Impfma\u00dfnahmen gegen SARS-CoV-2 und Influenza f\u00fcr Patienten mit chronischen Nierenkrankheiten. (2023). https:\/\/www.dgfn.eu\/bekanntmachungen-details\/empfehlung-zu-impfmassnahmen-gegen-sars-cov-2-und-influenza-fuer-patienten-mit-chronischen-nierenkrankheiten.html."},{"key":"60726_CR17","unstructured":"STIKO. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut 2025. Epid Bull 1\u201375 (2025)."},{"key":"60726_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12879-025-10613-2","volume":"25","author":"M Stapic","year":"2025","unstructured":"Stapic, M., Schulz, R. S., Tamayo-Cuartero, E., Kurth, T. & Brinks, R. Measuring the disease burden of seasonal influenza in Germany 2015\u20132020 using the incidence-based disability-adjusted life years (DALYs). BMC Infect. Dis. 25, 413 (2025).","journal-title":"BMC Infect. Dis."},{"key":"60726_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2215\/CJN.03700321","volume":"16","author":"C Speer","year":"2021","unstructured":"Speer, C. et al. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin. J. Am. Soc. Nephrol. 16, 1073\u20131082 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"60726_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/ndt\/gfab179","volume":"36","author":"B Simon","year":"2021","unstructured":"Simon, B. et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol. Dial Transpl. 36, 1709\u20131716 (2021).","journal-title":"Nephrol. Dial Transpl."},{"key":"60726_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.kint.2021.07.005","volume":"100","author":"M Espi","year":"2021","unstructured":"Espi, M. et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 100, 928\u2013936 (2021).","journal-title":"Kidney Int."},{"key":"60726_CR22","doi-asserted-by":"publisher","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","volume":"14","author":"MM Hossen","year":"2023","unstructured":"Hossen, M. M. et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front. Immunol. 14, 1198365 (2023).","journal-title":"Front. Immunol."},{"key":"60726_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbi.2019.09.024","volume":"83","author":"A Ledo","year":"2020","unstructured":"Ledo, A. et al. Elite athletes on regular training show more pronounced induction of vaccine-specific T-cells and antibodies after tetravalent influenza vaccination than controls. Brain Behav. Immun. 83, 135\u2013145 (2020).","journal-title":"Brain Behav. Immun."},{"key":"60726_CR24","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/eji.201242393","volume":"42","author":"T Schmidt","year":"2012","unstructured":"Schmidt, T. et al. CD4\u2009+\u2009T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur. J. Immunol. 42, 1755\u20131766 (2012).","journal-title":"Eur. J. Immunol."},{"key":"60726_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/S1473-3099(23)00690-4","volume":"24","author":"MV Stankov","year":"2024","unstructured":"Stankov, M. V. et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect. Dis. 24, e1\u2013e3 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"60726_CR26","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41467-024-47429-8","volume":"15","author":"R Urschel","year":"2024","unstructured":"Urschel, R. et al. SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4\/5 COVID-19-vaccination in previously infected and non-infected individuals. Nat. Commun. 15, 3077 (2024).","journal-title":"Nat. Commun."},{"key":"60726_CR27","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S1473-3099(23)00779-X","volume":"24","author":"U Marking","year":"2024","unstructured":"Marking, U. et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden. Lancet Infect. Dis. 24, e80\u2013e81 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"60726_CR28","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","volume":"230","author":"S Chalkias","year":"2024","unstructured":"Chalkias, S. et al. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines. J. Infect. Dis. 230, e279\u2013e286 (2024).","journal-title":"J. Infect. Dis."},{"key":"60726_CR29","doi-asserted-by":"crossref","unstructured":"Carreno, J. M. et al., XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. mBio, e0360724 (2025).","DOI":"10.1128\/mbio.03607-24"},{"key":"60726_CR30","doi-asserted-by":"publisher","first-page":"e1009928","DOI":"10.1371\/journal.ppat.1009928","volume":"17","author":"PA Debisarun","year":"2021","unstructured":"Debisarun, P. A. et al. Induction of trained immunity by influenza vaccination - impact on COVID-19. PLoS Pathog. 17, e1009928 (2021).","journal-title":"PLoS Pathog"},{"key":"60726_CR31","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","volume":"25","author":"S Moorlag","year":"2019","unstructured":"Moorlag, S., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473\u20131478 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"60726_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cell.2020.04.042","volume":"181","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell 181, 969\u2013977 (2020).","journal-title":"Cell"},{"key":"60726_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40001-023-01238-9","volume":"28","author":"A Shafiee","year":"2023","unstructured":"Shafiee, A. et al. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis. Eur. J. Med. Res. 28, 278 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"60726_CR34","doi-asserted-by":"crossref","unstructured":"Orru, S. et al., Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020. Euro Surveill 28 (2023).","DOI":"10.2807\/1560-7917.ES.2023.28.50.2300261"},{"key":"60726_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41541-023-00760-5","volume":"8","author":"C Xie","year":"2023","unstructured":"Xie, C., Yao, R. & Xia, X. The advances of adjuvants in mRNA vaccines. NPJ Vaccines. 8, 162 (2023).","journal-title":"NPJ Vaccines"},{"key":"60726_CR36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14760584.2024.2382725","volume":"23","author":"F Roman","year":"2024","unstructured":"Roman, F. et al. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev. Vaccines. 23, 715\u2013729 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"60726_CR37","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., O\u2019Hagan, D. T. & P, S.A. & Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov"},{"key":"60726_CR38","doi-asserted-by":"publisher","first-page":"E297","DOI":"10.1503\/cmaj.211881","volume":"194","author":"K Yau","year":"2022","unstructured":"Yau, K. et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ 194, E297\u2013E305 (2022).","journal-title":"CMAJ"},{"key":"60726_CR39","doi-asserted-by":"publisher","first-page":"108961","DOI":"10.1016\/j.clim.2022.108961","volume":"236","author":"H Karakizlis","year":"2022","unstructured":"Karakizlis, H. et al. Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clin. Immunol. 236, 108961 (2022).","journal-title":"Clin. Immunol."},{"key":"60726_CR40","doi-asserted-by":"publisher","first-page":"100371","DOI":"10.1016\/j.lanepe.2022.100371","volume":"17","author":"J Stumpf","year":"2022","unstructured":"Stumpf, J. et al. Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study. Lancet Reg. Health Eur. 17, 100371 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"60726_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","volume":"33","author":"F Sallusto","year":"2010","unstructured":"Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. Immunity 33, 451\u2013463 (2010).","journal-title":"Immunity"},{"key":"60726_CR42","doi-asserted-by":"publisher","first-page":"115907","DOI":"10.1016\/j.celrep.2025.115907","volume":"44","author":"R da Silva Antunes","year":"2025","unstructured":"da Silva Antunes, R. et al. Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters. Cell. Rep. 44, 115907 (2025).","journal-title":"Cell. Rep."},{"key":"60726_CR43","doi-asserted-by":"publisher","first-page":"115498","DOI":"10.1016\/j.celrep.2025.115498","volume":"44","author":"LM Molinos-Albert","year":"2025","unstructured":"Molinos-Albert, L. M. et al. Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic. Cell. Rep. 44, 115498 (2025).","journal-title":"Cell. Rep."},{"key":"60726_CR44","doi-asserted-by":"crossref","unstructured":"Bronder, S. et al., Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients. Am J. Transplant (2025).","DOI":"10.1016\/j.ajt.2025.09.023"},{"key":"60726_CR45","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ajt.2025.03.025","volume":"25","author":"J Havlin","year":"2025","unstructured":"Havlin, J. et al. Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4\u2009+\u2009T cell response in all vaccinees. Am. J. Transpl. 25, 1452\u20131460 (2025).","journal-title":"Am. J. Transpl."},{"key":"60726_CR46","unstructured":"Hall, V. G. et al., Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study. Clin Microbiol. Infect (2025)."},{"key":"60726_CR47","doi-asserted-by":"crossref","unstructured":"Radun, R. et al., Immunogenicity and reactogenicity of the adjuvanted respiratory syncytial virus vaccine in patients with chronic kidney disease. Clin Kidney J in press (2025).","DOI":"10.64898\/2025.12.02.25341408"},{"key":"60726_CR48","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","volume":"27","author":"T Schmidt","year":"2021","unstructured":"Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination. Nat. Med. 27, 1530\u20131535 (2021).","journal-title":"Nat. Med."},{"key":"60726_CR49","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1111\/ajt.16818","volume":"21","author":"T Schmidt","year":"2021","unstructured":"Schmidt, T. et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am. J. Transpl. 21, 3990\u20134002 (2021).","journal-title":"Am. J. Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60726-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:19:15Z","timestamp":1783343955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60726-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60726"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60726-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.S. has received grant support from Astellas and Biotest to the organization Saarland University outside the submitted work, and honoraria for lectures from Biotest, Takeda, Qiagen, MSD, and served in advisory boards for Moderna, Biotest, MSD and Takeda. T.S. has received travel support from Biotest. All other authors of this manuscript have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20771"}}